Recent developments in lipid-lowering therapy. Highlights from the Atorvastatin Landmark Program: Global Investigators Meeting III. June 1-3, 2004. Toronto, Canada.
The Atorvastatin Landmark Program: Global Investigators Meeting III was held June 1-3, in Toronto, Canada. The purpose of the meeting was to update investigators on the current status of the clinical trials that encompass the Atorvastatin Landmark Program. The main objectives were the following: 1. To review the range of studies that comprise the Atorvastatin Landmark Program. 2. To communicate recently completed study results and discuss the current and future impact of the findings, both individually and collectively, on clinical practice and guideline recommendations. 3. To discuss how the program is anticipated to evolve, highlighting new therapeutic modalities.
Bandyopadhyay
Prabirkumar
P
Sandwell & West Birmingham Hospitals NHS Trust, Lyndon, West Midlands B71 4HJ, UK. prabirbanerjee@yahoo.co.uk
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D017410:Practice Guidelines as Topic
D000924:Anticholesteremic Agents